Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

JNJ-95298177

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

J&J

Drug class:

Tubulin inhibitor, PSMA-targeted antibody-drug conjugate

Related drugs:

No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	JNJ-95298177 Sensitive: B - Late Trials JNJ-95298177 Sensitive : B	JNJ-95298177 Sensitive: B - Late Trials JNJ-95298177 Sensitive : B
FOLH1 overexpression	Prostate Cancer	FOLH1 overexpression	Prostate Cancer	JNJ-95298177 Sensitive: D – Preclinical JNJ-95298177 Sensitive : D	JNJ-95298177 Sensitive: D – Preclinical JNJ-95298177 Sensitive : D
PSMA1 expression	Prostate Cancer	PSMA1 expression	Prostate Cancer	JNJ-95298177 Sensitive: D – Preclinical JNJ-95298177 Sensitive : D	JNJ-95298177 Sensitive: D – Preclinical JNJ-95298177 Sensitive : D